GlassScriptPhysician profile
Amanda M Nevin
NPI 1083375182
$8,945.38
in general payments reported to CMS, 2019-2025
34 companies · $2,832 in 2025
The $2,832 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,505 · 2023: $1,555 · 2024: $1,054 · 2025: $2,832.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140 · Consulting Fee: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,140.17 |
| Consulting Fee | $1,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,041.68 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $1,206.91 | 2022-2025 | Hvad Pump Implant Kit |
| Abbvie INC. | $747.48 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $427.76 | 2023-2024 | Soliris, Ultomiris, Strensiq |
| Astrazeneca Pharmaceuticals LP | $372.35 | 2022-2025 | Fasenra |
| Neurocrine Biosciences, INC. | $341.86 | 2022-2023 | Ingrezza |
| Sanofi-Aventis U.S. LLC | $312.26 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $312.15 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $237.92 | 2022-2025 | |
| Novo Nordisk INC | $236.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $220.17 | 2023-2025 | Xarelto, Spravato |
| Biogen, INC. | $205.01 | 2022 | |
| Boston Scientific Corporation | $197.62 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $197.14 | 2022 | |
| Fresenius Kabi USA, LLC | $140.85 | 2024 | Kabiven |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $139.89 | 2025 | Tremfya |
| Dexcom, INC. | $121.15 | 2023 | Dexcom G7 Gss (161) |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.84 | 2024 | Caplyta |
| Alkermes, INC. | $120.00 | 2025 | Lybalvi |
| Hologic Sales and Service, LLC | $118.51 | 2025 | Aptima |
| Ultragenyx Pharmaceutical INC. | $118.44 | 2024 | Dojolvi |
| Jazz Pharmaceuticals INC. | $115.61 | 2022 | |
| Vertos Medical, INC. | $107.22 | 2023 | Mild Device Kit |
| Vertex Pharmaceuticals Incorporated | $96.66 | 2025 | |
| Sanofi Pasteur INC. | $96.63 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.33 | 2022 | |
| Aimmune Therapeutics, INC. | $85.52 | 2024 | |
| Nevro Corp. | $84.90 | 2022 | |
| Merck Sharp & Dohme LLC | $83.15 | 2023 | Keytruda |
| Emd Serono, INC. | $75.79 | 2024 | |
| Coloplast Corp | $75.66 | 2025 | |
| Solventum Corporation | $46.79 | 2024 | Activ.A.C. |
| Bayer Healthcare Pharmaceuticals INC. | $30.21 | 2024 | |
| Novartis Pharmaceuticals Corporation | $16.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Nevin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.